Business Description
Silexion Therapeutics Corp
ISIN : KYG1281K1067
Total Employee Number:
13Description
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.21 | |||||
Equity-to-Asset | 0.06 | |||||
Debt-to-Equity | 6.84 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 48 | |||||
3-Year EPS without NRI Growth Rate | 41.7 | |||||
3-Year FCF Growth Rate | 47.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 53.85 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.63 | |||||
9-Day RSI | 50.61 | |||||
14-Day RSI | 41.77 | |||||
3-1 Month Momentum % | -72.9 | |||||
6-1 Month Momentum % | -88.06 | |||||
12-1 Month Momentum % | -97.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1 | |||||
Quick Ratio | 1 | |||||
Cash Ratio | 0.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -273.6 | |||||
Shareholder Yield % | -242.96 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -513.24 | |||||
ROA % | -171.97 | |||||
ROIC % | -735.64 | |||||
3-Year ROIIC % | -1004.13 | |||||
ROC (Joel Greenblatt) % | -2754.48 | |||||
ROCE % | -276.07 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.07 | |||||
Price-to-Tangible-Book | 3.07 | |||||
EV-to-EBIT | -0.18 | |||||
EV-to-Forward-EBIT | -0.8 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-FCF | -0.2 | |||||
Earnings Yield (Greenblatt) % | -555.56 | |||||
FCF Yield % | -428.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLXN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Silexion Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -8.211 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 84.36 | ||
| 14-Day RSI | 41.77 | ||
| 14-Day ATR ($) | 0.330519 | ||
| 20-Day SMA ($) | 2.668 | ||
| 12-1 Month Momentum % | -97.4 | ||
| 52-Week Range ($) | 2.31 - 223.6 | ||
| Shares Outstanding (Mil) | 1.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Silexion Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Silexion Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 45 days | ||
| General meeting for 2026 | 2026-07-16 | 2.58 (+0.39%) | ||
| 0.1:1 Stock Split | 2026-05-29 | 4.28 (+4.55%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 4.99 (-15.05%) | ||
| Annual report for 2025 | 2026-03-17 | 15.70 (-3.32%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 15.70 (-3.32%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 28.10 (+1.08%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 76.00 (-8.32%) | ||
| 0.0666667:1 Stock Split | 2025-07-29 | 131.25 (-0.57%) |
Show
Entries
Silexion Therapeutics Corp Frequently Asked Questions
What is Silexion Therapeutics Corp(SLXN)'s stock price today?
The current price of SLXN is $2.64. The 52 week high of SLXN is $223.60 and 52 week low is $2.31.
When is next earnings date of Silexion Therapeutics Corp(SLXN)?
The next earnings date of Silexion Therapeutics Corp(SLXN) is 2026-08-31 Est..
Does Silexion Therapeutics Corp(SLXN) pay dividends? If so, how much?
Silexion Therapeutics Corp(SLXN) does not pay dividend.
Guru Commentaries on NAS:SLXN
No articles.
Press Release
Articles on Silexion Therapeutics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers